CIS Pharma offers a platform of different eye drop dispenser technologies designed for preservative-free drug formulations as eye-drops or as a spray. Devices to control eye-lids as well as digital technology to monitor drug dispense are available to improve the compliance of patients. The platform is a result of our expertise in ophthalmology: since the early eighties CIS Pharma has developed and licensed a number of drug substances for and to market leaders in ophthalmology. Our client’s drug products and respective dispensers have changed dramatically over that time.

The industry has seen significant improvements both in formulations as well as in new dispenser technology for such drugs. Today, preservative-free formulations improve the safety of chronically used drugs, e.g. glaucoma. Initially, the unpreserved formulations were offered in mono-doses for single-use, today multi-dose preservative-free products take over significant market share as a more economical solution with improved usability. At CIS Pharma, we also include digital technology such as sensors, databases and apps, to monitor drug intake and patient compliance. Very valuable information is derived from these digital processes, both during the clinical development as well as for drugs marketed.

CIS Pharma’s multi-dosing delivery platform is offering precise dosing of solutions from low to high viscosities. The fill volume is variable and the dispensed products may be delivered as a drop or as a stream. Furthermore, we offer an anti-microbial tip design reducing 5-log of colony forming units (CFU) within 1-2 hours, ensuring safety between each application.

eye drop dispenser technologies, eye-lid control, connectivity improve compliance.


The Cefuroxime Application System is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis. It meets the cataract surgeon’s need to dilute and inject 1mg cefuroxime in a safe, precise and standardized manner.

Every year, 20 million cataract patients receive an intraocular lens. Endophthalmitis, also called intravitreal infection, is a rare but severe inflammatory condition of the eye, caused by microbial contamination during the surgical procedure. The incidence is reported between 0.1% and 0.05% without intracameral antibiotic prophylaxis. The treatment of Endophthalmitis is expensive and one out of two patients lose sight or the eye.

Cefuroxime intracameral prophylaxis was found to reduce the risk of Endophthalmitis by a factor 5, whereas topical antibiotics have no effect on the outcome. Intracameral cefuroxime prophylaxis has gained adoption in cataract clinics across the globe. In Europe intracameral cefuroxime is part of the cataract surgery guideline and is approved in most countries.



CIS Pharma has developed the new standard of bio-inspired contact lens care solutions for cleaning, disinfection and storage of silicone hydrogel contact lenses. Compared to market leaders, the product shows superior disinfecting power. In addition, the product offers an innovative comfort-agent complex that delivers an unsurpassed amount of hyaluronic acid to the contact lens surface. The complex includes a physiological mix of minerals for protection and regeneration of corneal cells.

In the standalone test, our product shows a superior disinfection potential for various bacteria & fungi related to eye infections. The study confirmed that only a minimal period of time was required for complete inactivation of microbes. The solution keeps its disinfection potential over several weeks, even if contamination occurs again, a safety net for non-compliant users. The product is highly effective against the active trophozoite as well as the stress resistant cyst forms of acanthamoeba, responsible for severe eye infections that may lead to blindness.

The product forms a depot on the contact lens responsible for long-lasting increase of lens wettability. It offers a unique comfort agent complex that delivers an unsurpassed amount of hyaluronic acid to the contact lens surface. Bio-compatibility shows the product is far better tolerated than state of the art products, evidenced by comparison of conjunctival redness and conjunctival and corneal staining.